Cargando…

Identification of a Novel Four and a Half LIM Domain 1 Mutation in a Chinese Male Presented with Hypertrophic Cardiomyopathy and Mild Skeletal Muscle Hypertrophy

Detalles Bibliográficos
Autores principales:	Zhang, Bing-Qing, Si, Nuo, Liu, Dong-Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717995/ https://www.ncbi.nlm.nih.gov/pubmed/26265627 http://dx.doi.org/10.4103/0366-6999.162493

Ejemplares similares

Four and a Half LIM Domains 2 (FHL2) Contribute to the Epithelial Ovarian Cancer Carcinogenesis
por: Wang, Chen, et al.
Publicado: (2020)

Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression
por: Wei, Xiaofan, et al.
Publicado: (2020)

Four-and-a-half LIM domains proteins are novel regulators of the protein kinase D pathway in cardiac myocytes
por: Stathopoulou, Konstantina, et al.
Publicado: (2014)

Four-And-A-Half LIM-Domain Protein 2 (FHL2) Deficiency Aggravates Cholestatic Liver Injury
por: Sommer, Judith, et al.
Publicado: (2020)

The Enterococcus faecalis virulence factor ElrA interacts with the human Four-and-a-Half LIM Domains Protein 2
por: Jamet, Alexandre, et al.
Publicado: (2017)

Deficiency in four and one half LIM domain protein 2 (FHL2) aggravates liver fibrosis in mice
por: Huss, Sebastian, et al.
Publicado: (2013)

LIM and cysteine-rich domains 1 (LMCD1) regulates skeletal muscle hypertrophy, calcium handling, and force
por: Ferreira, Duarte M. S., et al.
Publicado: (2019)

Case Report: Novel LIM domain-binding protein 3 (LDB3) mutations associated with hypertrophic cardiomyopathy family
por: Zheng, Junmin, et al.
Publicado: (2022)

Dral Is a P53-Responsive Gene Whose Four and a Half Lim Domain Protein Product Induces Apoptosis
por: Scholl, Florence A., et al.
Publicado: (2000)

Hypertrophic cardiomyopathy with little hypertrophy and severe arrhythmia
por: Ripoll-Vera, Tomas, et al.
Publicado: (2018)

Atypical Infantile-onset Pompe Disease with Hypertrophic Cardiomyopathy
por: Quan, Jun-Jun, et al.
Publicado: (2017)

New Variant With a Previously Unrecognized Mechanism of Pathogenicity in Hypertrophic Cardiomyopathy
por: Aguib, Yasmine, et al.
Publicado: (2021)

Hemorrhagic stroke caused by moyamoya disease in a patient with obstructive hypertrophic cardiomyopathy
por: Liu, Sheng, et al.
Publicado: (2021)

Infective endocarditis in obstructive hypertrophic cardiomyopathy: a case series and literature review
por: Wu, Zi-Wen, et al.
Publicado: (2021)

The Four and a Half LIM-Domain 2 Controls Early Cardiac Cell Commitment and Expansion Via Regulating β-Catenin-Dependent Transcription
por: Renger, Anke, et al.
Publicado: (2013)

Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohort
por: Galindo-Feria, Angeles S, et al.
Publicado: (2022)

The four and a half LIM domains 2 (FHL2) regulates ovarian granulosa cell tumor progression via controlling AKT1 transcription
por: Hua, G, et al.
Publicado: (2016)

Subaortic and midventricular obstructive hypertrophic cardiomyopathy with extreme segmental hypertrophy
por: Efthimiadis, Georgios K, et al.
Publicado: (2007)

Extreme septal hypertrophy in an adolescent with congenital familial hypertrophic cardiomyopathy
por: Park, Byoung-Won, et al.
Publicado: (2015)

Atrial Fibrillation in Hypertrophic Cardiomyopathy: Is the Extent of Septal Hypertrophy Important?
por: Park, Kyoung-min, et al.
Publicado: (2016)

Hypertrophy of the Male Breast
por: Paparow, C.
Publicado: (1917)

Caseous mitral valve calcification and concurrent hypertrophic obstructive cardiomyopathy: A rare cause of stroke
por: Ullah, Waqas, et al.
Publicado: (2020)

Four and a Half LIM Domains 1b (Fhl1b) Is Essential for Regulating the Liver versus Pancreas Fate Decision and for β-Cell Regeneration
por: Xu, Jin, et al.
Publicado: (2016)

ACT-A: half empty or half full?
por: Shisana, Olive, et al.
Publicado: (2022)

Reversible Apical Hypertrophy in a Young Competitive Athlete with Familiar Hypertrophic Cardiomyopathy
por: Di Gioia, Giuseppe, et al.
Publicado: (2023)

The effect of inhibition of the Na(+)/H(+) exchanger on the development of hypertrophy in hypertrophic cardiomyopathy
por: Brouwer, Wessel P, et al.
Publicado: (2011)

Effect of hypertrophy on left ventricular diastolic function in patients with hypertrophic cardiomyopathy
por: CIAMPI, QUIRINO, et al.
Publicado: (2006)

Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy
por: Monserrat, Lorenzo, et al.
Publicado: (2011)

Electro‐ and echocardiographic features of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy
por: Bula, Karolina, et al.
Publicado: (2022)

Four-and-a-Half LIM-Domain Protein 2 (FHL2) Induces Neuropeptide Y (NPY) in Macrophages in Visceral Adipose Tissue and Promotes Diet-Induced Obesity
por: Sommer, Judith, et al.
Publicado: (2023)

Are there sex differences following treatment of left ventricular outflow tract obstruction in adults with hypertrophic cardiomyopathy?
por: Chahal, Anwar A., et al.
Publicado: (2017)

Hypertrophic Cardiomyopathy: Prevalence, Hypertrophy Patterns, and Their Clinical and ECG Findings in a Hospital at Qatar
por: Helmy, Sherif M., et al.
Publicado: (2011)

Increased Postnatal Cardiac Hyperplasia Precedes Cardiomyocyte Hypertrophy in a Model of Hypertrophic Cardiomyopathy
por: Farrell, Emily T., et al.
Publicado: (2017)

Regression of Left Ventricular Hypertrophy in a Case of Sarcomeric Hypertrophic Cardiomyopathy: An Unexpected Outcome
por: Cabrera Borrego, Eva, et al.
Publicado: (2020)

Analysis of the Drosophila Ajuba LIM protein defines functions for distinct LIM domains
por: Rauskolb, Cordelia, et al.
Publicado: (2022)

Left Ventricular Hypertrophy and Hypertrophic Cardiomyopathy in Adult Solid Organ Transplant Recipients
por: Reza, Nosheen, et al.
Publicado: (2021)

Left ventricular anatomy in obstructive hypertrophic cardiomyopathy: beyond basal septal hypertrophy
por: Hermida, Uxio, et al.
Publicado: (2022)

A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy
por: Shelke, Abhijeet B., et al.
Publicado: (2016)

MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy
por: Huang, Derong, et al.
Publicado: (2020)

Comparison of the Clinical Features of Apical Hypertrophic Cardiomyopathy Versus Asymmetric Septal Hypertrophy in Korea
por: Yang, Hyun Suk, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_b3ntdu14j58kfjus1hnrric6qo